Exploration of the CuAAC Reaction for the Synthesis of Novel 3-(Triazol-1-yl)methyl-imidazo[1,2-a]pyridines

Poonam Khedar; Kasiviswanadharaju Pericherla; Anil Kumar

doi:10.1055/s-0032-1317379

Synlett, Table of Contents

Synlett 2012; 23(18): 2609-2614
DOI: 10.1055/s-0032-1317379

letter

Exploration of the CuAAC Reaction for the Synthesis of Novel 3-(Triazol-1-yl)methyl-imidazo[1,2-a]pyridines

Poonam Khedar

Department of Chemistry, Birla Institute of Technology and Science, Pilani 333 031, Rajasthan, India Fax: +91(1596)244183 Email: anilkumar@bits-pilani.ac.in

,

Kasiviswanadharaju Pericherla

Department of Chemistry, Birla Institute of Technology and Science, Pilani 333 031, Rajasthan, India Fax: +91(1596)244183 Email: anilkumar@bits-pilani.ac.in

,

Anil Kumar*

Department of Chemistry, Birla Institute of Technology and Science, Pilani 333 031, Rajasthan, India Fax: +91(1596)244183 Email: anilkumar@bits-pilani.ac.in

› Author Affiliations

Abstract

All articles of this category

Abstract

The archetypical CuAAC click chemistry is explored to assemble diverse 3-(triazol-1-yl)methyl-imidazo[1,2-a]pyridines. The approach is simple, general, and environmentally benign to generate a library of novel triazolo-imidazo[1,2-a]pyridine derivatives in good yield (30–90%).

Key words

azides - click chemistry - imidazo[1,2-a]pyrimidine 1,2,3-triazole - 3-(triazolyl)methyl-imidazo[1,2-a]pyridine

Full Text

References

References and Notes
1 Kolb HC, Finn MG, Sharpless KB. Angew. Chem. Int. Ed. 2001; 40: 2004
2 Stefani HA, Silva NC. S, Manarin F, Lüdtke DS, Zukerman-Schpector J, Madureira LS, Tiekink ER. T. Tetrahedron Lett. 2012; 53: 1742
3 Kolb HC, Sharpless KB. Drug Discovery Today 2003; 8: 1128
4 van Dijk M, Rijkers DT. S, Liskamp RM. J, van Nostrum CF, Hennink WE. Bioconjugate Chem. 2009; 20: 2001
5 Lutz J.-F, Zarafshani Z. Adv. Drug. Delivery Rev. 2008; 60: 958
6 Best MD. Biochemistry 2009; 48: 6571
7 Al-Tel TH, Al-Qawasmeh RA, Zaarour R. Eur. J. Med. Chem. 2011; 1874
8 Fisher MH, Lusi A. J. Med. Chem. 1972; 15: 982
9 Chezal J.-M, Paeshuyse J, Gaumet V, Canitrot D, Maisonial A, Lartigue C, Gueiffier A, Moreau E, Teulade J.-C, Chavignon O, Neyts J. Eur. J. Med. Chem. 2010; 2044
10 Dahan-Farkas N, Langley C, Rousseau AL, Yadav DB, Davids H, de Koning CB. Eur. J. Med. Chem. 2011; 4573
11 Hamdouchi C, Ezquerra J, Vega JA, Vaquero JJ, Alvarez-Builla J, Heinz BA. Bioorg. Med. Chem. Lett. 1999; 9: 1391
12 Moraski GC, Markley LD, Chang M, Cho S, Franzblau SG, Hwang CH, Boshoff H, Miller MJ. Bioorg. Med. Chem. 2012; 20: 2214
13 Kaminski JJ, Hilbert JM, Pramanik BN, Solomon DM, Conn DJ, Rizvi RK, Elliott AJ, Guzik H, Lovey RG. J. Med. Chem. 1987; 30: 2031
14 Kaminski JJ, Bristol JA, Puchalski C, Lovey RG, Elliott AJ, Guzik H, Solomon DM, Conn DJ, Domalski MS. J. Med. Chem. 1985; 28: 876
15 Kaminski JJ, Doweyko AM. J. Med. Chem. 1997; 40: 427
16 Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW. J. Med. Chem. 2004; 47: 3658
17 Goodacre SC, Street LJ, Hallett DJ, Crawforth JM, Kelly S, Owens AP, Blackaby WP, Lewis RT, Stanley J, Smith AJ, Ferris P, Sohal B, Cook SM, Pike A, Brown N, Wafford KA, Marshall G, Castro JL, Atack JR. J. Med. Chem. 2005; 49: 35
18 Starr JT, Sciotti RJ, Hanna DL, Huband MD, Mullins LM, Cai H, Gage JW, Lockard M, Rauckhorst MR, Owen RM, Lall MS, Tomilo M, Chen H, McCurdy SP, Barbachyn MR. Bioorg. Med. Chem. Lett. 2009; 19: 5302
19 Emmitte KA, Wilson BJ, Baum EW, Emerson HK, Kuntz KW, Nailor KE, Salovich JM, Smith SC, Cheung M, Gerding RM, Stevens KL, Uehling DE, Mook RA. Jr, Moorthy GS, Dickerson SH, Hassell AM, Anthony Leesnitzer M, Shewchuk LM, Groy A, Rowand JL, Anderson K, Atkins CL, Yang J, Sabbatini P, Kumar R. Bioorg. Med. Chem. Lett. 2009; 19: 1004
20 Warshakoon NC, Wu S, Boyer A, Kawamoto R, Sheville J, Renock S, Xu K, Pokross M, Evdokimov AG, Walter R, Mekel M. Bioorg. Med. Chem. Lett. 2006; 16: 5598
21 Zimmermann PJ, Buhr W, Brehm C, Palmer AM, Feth MP, Senn-Bilfinger J, Simon W.-A. Bioorg. Med. Chem. Lett. 2007; 17: 5374
22 Gedda K, Briving C, Svensson K, Maxvall I, Andersson K. Biochem. Pharmacol. 2007; 73: 198
23 Odell LR, Nilsson MT, Gising J, Lagerlund O, Muthas D, Nordqvist A, Karlén A, Larhed M. Bioorg. Med. Chem. Lett. 2009; 19: 4790
24 Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG. G, Shipman CM. Int. J. Cancer 2006; 119: 1254
25 Takeuchi M, Sakamoto S, Kawamuki K, Kurihara H, Nakahara H, Isomura Y. Chem. Pharm. Bull. 1998; 46: 1703
26 Hamdouchi C, Zhong B, Mendoza J, Collins E, Jaramillo C, De Diego JE, Robertson D, Spencer CD, Anderson BD, Watkins SA, Zhang F, Brooks HB. Bioorg. Med. Chem. Lett. 2005; 15: 1943
27 Byth KF, Culshaw JD, Green S, Oakes SE, Thomas AP. Bioorg. Med. Chem. Lett. 2004; 14: 2245
28 Wang X.-L, Wan K, Zhou C.-H. Eur. J. Med. Chem. 2010; 4631
29 Jordão AK, Afonso PP, Ferreira VF, de Souza MC. B. V, Almeida MC. B, Beltrame CO, Paiva DP, Wardell SM. S. V, Wardell JL, Tiekink ER. T, Damaso CR, Cunha AC. Eur. J. Med. Chem. 2009; 3777
30 Tripathi RP, Yadav AK, Ajay A, Bisht SS, Chaturvedi V, Sinha SK. Eur. J. Med. Chem. 2010; 142
31 Boechat N, Ferreira VF, Ferreira SB, Ferreira Md. L. G, da Silva Fd. C, Bastos MM, Costa Md. S, Lourenço MC. S, Pinto AC, Krettli AU, Aguiar AC, Teixeira BM, da Silva NV, Martins PR. C, Bezerra FA. F. M, Camilo AL. S, da Silva GP, Costa CC. P. J. Med. Chem. 2011; 54: 5988
32 Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Vullo D, Supuran CT, Poulsen S.-A. J. Med. Chem. 2007; 50: 1651
33 Kumar A, Ahmad I, Chhikara BS, Tiwari R, Mandal D, Parang K. Bioorg. Med. Chem. Lett. 2011; 21: 1342
34 Olesen PH, Sørensen AR, Ursø B, Kurtzhals P, Bowler AN, Ehrbar U, Hansen BF. J. Med. Chem. 2003; 46: 3333
35 Röhrig UF, Majjigapu SR, Grosdidier A, Bron S, Stroobant V, Pilotte L, Colau D, Vogel P, Van den Eynde BJ, Zoete V, Michielin O. J. Med. Chem. 2012; 55: 5270
36 Patpi SR, Pulipati L, Yogeeswari P, Sriram D, Jain N, Sridhar B, Murthy RT. A. D, Kalivendi SV, Kantevari S. J. Med. Chem. 2012; 55: 3911
37 Manfredini S, Beatrice VicentiniC, Manfrini M, Bianchi N, Rutigliano C, Mischiati C, Gambari R. Bioorg. Med. Chem. 2000; 8: 2343
38 Spiteri C, Moses JE. Angew. Chem. Int. Ed. 2010; 49: 31
39 General Procedure for the Preparation of 3-(Triazol-1-yl)methyl-imidazo[1,2-a]pyridines (6) To a 25 mL round-bottom flask was added 3-(azidomethyl)-2-pheny-lH-imidazo[1,2-a]pyridine (1.0 mmol), phenylacetylene (1.2 mmol), CuI (0.05 mmol), and PEG-400–H₂O (1:1 v/v) (10 mL). The resulting mixture was stirred at r.t. for 5–7 h. After completion of the reaction H₂O (20 mL) was added to the reaction mixture and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over anhyd Na₂SO₄ and evaporated the volatiles. The crude was purified by column over silica gel to give 6.
40 Spectroscopic Data of Selected Compounds 6 Compound 6b: ¹H NMR (500 MHz, CDCl₃): δ = 8.16 (d, J = 6.8 Hz, 1 H), 7.72 (d, J = 9.1 Hz, 1 H), 7.69 (dd, J = 3.3, 1.1 Hz, 1 H), 7.68–7.66 (m, 5 H), 7.50 (s, 1 H), 7.35–7.31 (m, 1 H), 6.92 (d, J = 1.7 Hz, 1 H), 6.90 (t, J = 3.2 Hz, 2 H), 6.02 (s, 2 H), 3.82 (s, 3 H). ¹³C NMR (126 MHz, CDCl₃): δ = 159.8, 148.6, 132.3, 132.1, 131.2, 130.0, 128.6, 127.0, 126.5, 123.8, 123.2, 122.6, 117.8, 117.8, 114.2, 113.8, 105.4, 55.3, 43.9. ESI-MS: m/z = 460 [M + H]⁺. Compound 6d: ¹H NMR (500 MHz, DMSO-d ₆): δ = 8.73 (s, 1 H), 8.69 (s, 2 H), 8.37 (s, 1 H), 8.27 (d, J = 7.3 Hz, 1 H), 7.83 (d, J = 6.9 Hz, 4 H), 7.47–7.39 (m, 3 H), 7.31 (t, J = 6.9 Hz, 1 H), 7.09 (d, J = 5.4 Hz, 1 H), 6.26 (s, 2 H). ¹³C NMR (126 MHz, DMSO-d ₆): δ = 148.6, 147.0, 134.6, 130.9, 129.3, 128.5, 126.9, 125.7, 124.5, 123.2, 123.1, 122.0, 122.0, 117.7, 113.8, 43.5. ESI-MS: m/z = 397 [M + H]⁺. Compound 6j: ¹H NMR (500 MHz, CDCl₃): δ = 8.12 (d, J = 6.7 Hz, 1 H), 7.70 (d, J = 9.0 Hz, 1 H), 7.65 (d, J = 8.3 Hz, 2 H), 7.46 (d, J = 8.2 Hz, 2 H), 7.31 (dd, J = 8.4, 7.4 Hz, 1 H), 7.26–7.25 (m, 1 H), 7.24 (s, 1 H), 7.19 (t, J = 5.5 Hz, 3 H), 7.05 (s, 1 H), 6.89 (t, J = 6.8 Hz, 1 H), 5.91 (s, 2 H), 4.02 (s, 2 H).¹³C NMR (126 MHz, CDCl₃): δ = 148.5, 145.1, 138.6, 134.8, 131.6, 130.6, 129.8, 129.4, 129.2, 128.6, 128.6, 126.6, 126.3, 123.9, 120.6, 117.8, 113.6, 43.8, 32.2. ESI-MS: m/z = 400 [M + H]⁺. Compound 6k: ¹H NMR (500 MHz, CDCl₃): δ = 8.12 (d, J = 6.8 Hz, 1 H), 7.70 (t, J = 8.9 Hz, 3 H), 7.49 (d, J = 8.4 Hz, 2 H), 7.33–7.29 (m, 1 H), 7.10 (s, 1 H), 6.89 (t, J = 6.7 Hz, 1 H), 5.95 (s, 2 H), 2.63 (t, J = 7.6 Hz, 2 H), 1.64–1.62 (m, 2 H), 0.91 (t, J = 7.4 Hz, 3 H). ¹³C NMR (126 MHz, CDCl₃): δ = 149.3, 143.0, 134.8, 131.8, 129.7, 129.3, 126.2, 125.9, 125.4, 123.8, 119.8, 117.8, 113.6, 43.7, 27.7, 22.6, 13.7. ESI-MS: m/z = 352 [M + H]⁺. Compound 6o: ¹H NMR (500 MHz, CDCl₃): δ = 8.13 (d, J = 6.7 Hz, 1 H), 7.73 (dd, J = 7.9, 5.4 Hz, 5 H), 7.55 (s, 1 H), 7.34–7.29 (m, 1 H), 7.07 (dd, J = 9.4, 8.2 Hz, 4 H), 6.89 (t, J = 6.7 Hz, 1 H), 6.04 (s, 2 H), 3.88 (s, 3 H). ¹³C NMR (126 MHz, CDCl₃): δ = 160.2, 147.8, 145.6, 130.9, 129.8, 128.8, 127.5, 127.5, 126.3, 125.3, 123.7, 118.5, 117.5, 115.9, 115.8, 114.6, 113.6, 55.4, 44.1. ESI-MS: m/z = 400 [M + H]⁺.

Supplementary Material

Supporting Information